Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04826484 · ClinicalTrials.gov registry record · Phase 3
Opioid Reduction Initiative During Outpatient Pediatric Urologic Procedures Using Exparel
A Phase 3 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 104
- Enrollment target
NCT04826484: Clinical Trial Phase 3 study, sponsored by Johns Hopkins University.
NCT04826484 is a Phase 3 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 104 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04826484, a Phase 3 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 104 participants
- Enrollment target
Study Summary
This study aims to evaluate the utility of long-acting liposomal bupivacaine (Exparel®) in improving pain scores and reducing narcotic pain requirements in pediatric patients following minor urologic procedures.
Primary Outcome
Percentage of patients who are opiate-free at 48 hours postoperatively.
Interventions
- DRUG Bupivacaine Hydrochloride
- DRUG Exparel 133 miligrams per 10 milliliter injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2023-04-26 |
| Phase | Phase 3 |
Why NCT04826484 stopped before completion
NCT04826484 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Bupivacaine Hydrochloride is the first listed.
NCT04826484 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04826484 about?
NCT04826484 is a clinical study titled "Opioid Reduction Initiative During Outpatient Pediatric Urologic Procedures Using Exparel". This study aims to evaluate the utility of long-acting liposomal bupivacaine (Exparel®) in improving pain scores and reducing narcotic pain requirements in pediatric patients following minor urologic procedures.
What is the current status of trial NCT04826484?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 104 participants. The study started on 2021-10-01. Estimated completion is 2023-04-26.
What interventions are being tested in trial NCT04826484?
The interventions under investigation include: Bupivacaine Hydrochloride (DRUG), Exparel 133 miligrams per 10 milliliter injection (DRUG).
Who is sponsoring clinical trial NCT04826484?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04826484's enrollment target sits among peer trials
104 1671st of 2000 higher than 327 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI